Unknown

Dataset Information

0

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.


ABSTRACT: Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease.

SUBMITTER: Panarese JD 

PROVIDER: S-EPMC6421540 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu<sub>4</sub> PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive <i>in vitro</i> and <i>in vivo</i> pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate  ...[more]

Similar Datasets

| S-EPMC4789665 | biostudies-literature
| S-EPMC4492464 | biostudies-literature
| S-EPMC5031509 | biostudies-literature
| S-EPMC5304297 | biostudies-literature
| S-EPMC6047034 | biostudies-literature
2022-01-03 | GSE182592 | GEO
| S-EPMC8689142 | biostudies-literature
| S-EPMC6690704 | biostudies-literature
2019-08-13 | GSE135762 | GEO
| S-EPMC4094264 | biostudies-literature